SOLIRIS (eculizumab): The first treatment specifically approved for PNH

How Does SOLIRIS Work?

Is SOLIRIS right for me?

SOLIRIS® (eculizumab) works by blocking a part of the immune system called the "complement" system. By blocking complement, SOLIRIS reduces the destruction of red blood cells (hemolysis) and therefore improves the symptoms of PNH.

How SOLIRIS WorksIn clinical studies, SOLIRIS blocked hemolysis in every PNH patient and all patients sustained a reduction in hemolysis for the entire time they were taking SOLIRIS, ranging from 10 to 54 months.

Since PNH is a chronic disease, SOLIRIS is intended to be an ongoing therapy. Patients who start SOLIRIS should continue to take it even if they feel better. If for some reason you and your doctor determine that you should stop SOLIRIS therapy, only your doctor can safely manage taking you off the drug.

 


Want answers to common SOLIRIS questions? See our FAQs here.

Because SOLIRIS blocks part of the immune system, you may be at an increased risk for certain infections during SOLIRIS treatment. Your doctor will give you important safety information about SOLIRIS. You will need to have all recommended immunizations and vaccines before you start treatment with SOLIRIS.

Next: Taking SOLIRIS

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.